Von Willebrand factor multimer composition is modified following oral methionine load in women with thrombosis, but not in healthy women

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 4, 2005, Pages 267-273

  Perutelli, Paolo ^a   Amato, Stefano ^a   Minniti, Giuseppe ^b   Bottini, Federico ^a   Calevo, Maria G ^a   Cerone, Roberto ^b   Molinari, Angelo C ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Hyperhomocysteinemia; Methionine loading test; Thrombosis von Willebrand factor

Indexed keywords

HOMOCYSTEINE; METHIONINE; VON WILLEBRAND FACTOR;

ADULT; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM LESION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOSIS; VEIN THROMBOSIS;

EID: 18944383208     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000169219.93054.92     Document Type: Article

References (26)

1. Boushey C, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274:1049-1057.
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-1050.
3. Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 2001; 36(suppl):S13-S26.
4. Cattaneo M. Hyperhomocysteinemia: an important risk factor for cardiovascular disease? Potentially, yes. J Thromb Haemost 2003; 1:1878-1879.
5. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91:4158-4163.
6. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96:2542-2544.
7. Constans J, Blann AD, Resplandy F, Parrot F, Seigneur M, Renard M, et al. Endothelial dysfunction during acute methionine load in hyperhomocysteinaemic patients. Atherosclerosis 1999; 147:411-413.
8. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281:113-118.
9. Heydrick SJ, Weiss N, Thomas SR, Cap AP, Pimentel DR, Loscalzo J, et al. L-homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Radic Biol Med 2004; 36:632-640.
10. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Practice Res Clin Haematol 2001; 14:257-279.
11. Furlan M. Proteolytic cleavage of von Willebrand factor by ADAMTS-13 prevents uninvited clumping of blood platelets. J Thromb Haemost 2004; 2:1505-1509.
12. Marongiu F, Fenu L, Pisu G, Contu P, Barcellona D. Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? Haematologica 2003; 88:186-191.
13. Minniti G, Piana A, Armani U, Cerone R. Determination of plasma and serum homocysteine by high-performance liquid chromatography with fluorescence detection. J Chromatogr A 1998; 828:401-405.
14. Perutelli P. Proteolysis of von Willebrand factor is increased during cardiopulmonary bypass. Thromb Res 2001; 102:467-473.
15. Perutelli P. Immunostaining of von Willebrand factor multimers on agarose gels and nitrocellulose filters. Haematologica 2002; 87:223-224.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
17. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88:774-782.
18. Tsai H-M, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83:2171-2179.
19. Gerdes VEA, Kremer Hovinga HA, Ten Gate H, Macgillavry MR, Leijte A, Reitsma PH, et al. Homocysteine and markers of coagulation and endothelial cell activation. J Thromb Haemost 2004; 2:445-451.
20. de Jong SC, Stehouwer CDA, Van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997; 78:1332-1337.
21. Denis CV, Terraube V, Robert K, Janel N. Elevated plasma von Willebrand factor in a murine model of severe hyperhomocysteinemia. Thromb Haemost 2003; 90:362-363.
22. Dong J-F, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033-4039.
23. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70:380-385.
24. Coppola R, Mari D, Lattuada A, Franceschi C. von Willebrand factor in Italian centenarians. Haematologica 2003; 88:39-43.
25. Perutelli P, Lerzo F, Calza G, Cevasco M, Mori PG. Abnormalities of plasma von Willebrand factor multimeric structure induced by extracorporeal circulation. Haematologica 1999; 84:287-288.
26. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102:1290-1295.